All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On October 19, 2021, the U.S. Food and Drug Administration (FDA) approved an abbreviated new drug application for a generic version of lenalidomide capsules, a thalidomide analogue, for oral use in patients with multiple myeloma (MM) and myelodysplastic syndromes (MDS).1 The approval includes 2.5 mg and 20 mg strengths, and a tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths.
Lenalidomide capsules are used for the treatment of adult patients with:
You can find the full prescribing, safety information and black box warning here.
Subscribe to get the best content related to MDS delivered to your inbox